Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

SUPN - Supernus Pharmaceuticals, Inc.... | Finranks

Home

/

SUPN

S

Supernus Pharmaceuticals, Inc. (SUPN)

NGM – Цена в реальном времени. Валюта: USD

50.53

+1.16 (2.35%)

При закрытии: May 12, 2026, 4:00 PM EDT

50.83

+0.30 (0.59%)

До открытия: May 13, 2026, 7:50 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.

Supernus Announces First Quarter 2026 Financial Results

Supernus Announces First Quarter 2026 Financial Results

ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Видео

No Data

There is no data to display

Пресс-релизы

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

Supernus Announces First Quarter 2026 Financial Results

Supernus Announces First Quarter 2026 Financial Results

ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively.

Lunai Bioworks, Inc. Issues Letter to Shareholders

Lunai Bioworks, Inc. Issues Letter to Shareholders

SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial.